To clarify the role of allelic loss on chromosome arm 13q in lymphomagenesis, we performed fluorescence in situ hybridization (FISH) analysis of a total of 43 primary lymphomas, including both indolent and aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD), using the specific probes at RB1 and D13S319 loci on the centromeric portion of chromosome arm 13q. Monosomy at either or both RB1 and D13S319 loci was detected in 15 of 43 (35%) lymphomas (14 of 43 cases at RB1 locus and seven of 43 cases at D13S319 locus); the 13q deletion was frequently detected in the aggressive NHLs (40%; 12 of 30 cases) compared with that in indolent NHL (17%; one of six cases) and a subset of HD (29%; two of seven cases). There are only six cases of 43 which have total monosomy 13q14, all aggressive NHL, 14% of total or 20% of this subgroup. In addition, we analyzed the loss of heterozygosity in 15 of the 43 primary lymphoma samples for several polymorphic microsatellite loci (D13S168, RB1 and D13S272) on the chromosome arm 13q, and confirmed the 13q deletion in four of five cases that were positive on FISH analysis. The subchromosomal region frequently altered in lymphoma on 13q14 is the region around RB1 locus and centromeric to D13S319 locus, which is an overlapped region frequently deleted in chronic lymphocytic leukemia. Together, our data indicate that the 13q alterations are present in a variety of types of lymphoma and occur in a significant proportion of aggressive NHLs, suggesting the possible presence of common candidate gene(s) on the 13q14 region, whose alteration may play an important role in the formation or development of a wide variety of mature lymphoid malignancies.
Introduction
Diffuse large cell lymphoma (DLCL) is the most frequent subtype of lymphoma, making up approximately 50% of nonHodgkin's lymphoma (NHL), and it is highly heterogeneous with respect to karyotypic abnormalities and underlying molecular regions. 1 The most frequent genetic alterations detected in DLCL to date are the abnormalities involving the BCL6 gene, which was isolated from the breakpoint of t(3;14) (q27; q32); the BCL6 gene rearrangement has been reported in a relatively high proportion (29-37%) of DLCLs, and in some (13-17%) indolent and transformed follicular lymphomas. 2, 3 Low-grade follicular B-NHL is associated with the t(14;18) (q32.3; q21.3) involving the BCL2 gene, mantle cell B-NHL with t(11;14) (q13;q32.3) involving BCL1/CCND1, and Burkitt's lymphoma with t(8; 14)(q24.1; q32.3) involving the MYC oncogene. Both t(14; 18) and t (8; 14) have been discovered to be also involved in 10% and 20% of DLCL, respectively. 1, 4 Although these alterations related to the activation of oncogenes through translocation are believed to be the most frequent mechanism in primary lymphomagenesis, little is known about the molecular basis of lymphoma progression, which has been a major concern among hematologic oncolo- gists. 1, 4 It is now well accepted that tumor progression is based on the accumulation of genetic alterations in tumor cells, and that the acquired inactivations of recessive tumor suppressor genes (TSGs) are one of the candidate mechanisms of tumor progression;
5 p53 mutations are frequently associated with the NHL which display clinical progression and histologic transformation; p53 gene was found to be mutated in at least 25% of transformed follicular lymphomas, and in 30% of aggressive variants of mantle cell lymphoma. [6] [7] [8] [9] Moreover, Ichikawa et al 10 recently revealed that the mutation of the p53 gene was significantly associated with a poor prognosis in patients with aggressive B-NHL, by multivariate analysis. Although the frequency of p15 and p16 alterations in lymphomas is not high (15%), [11] [12] [13] [14] it was found by Garcia-Sanz et al, 15 using a multivariate analysis that the presence of p16 gene abnormalities was associated with a shorter survival in NHL. It was also suggested that the hypermethylation of p16 gene in addition to deletions and mutations is associated with aggressive NHL. 16 The deletion of all or a part of 6q (6q25-27 or 6q21-23) was detected in 20% of a variety of B-NHL cases. 17 It was suggested that deletions in 6q21 are associated with highgrade lymphoma, deletions of 6q25-27 with intermediategrade lymphoma and deletions of 6q23 with low-grade NHL without t(14;18). 18 Brown et al 19 reported that a cell line derived from a lowgrade B cell lymphoma showed 13q14 deletion in addition to a translocation of t (11;14) . Together with their results regarding chronic lymphocytic leukemia (CLL), they emphasized the contribution of a TSG at 13q14 to the initiation or progression of low-grade B cell malignancies, and suggested that it be named DBM (disrupted in B cell malignancy). Liu et al 20 reported that 13q14 deletions were found not only in three of 12 follicular lymphomas, but also in an additional high-grade T cell lymphoma. Dreyling et al 21 recently reported the hemizygous deletion of the RB1 locus in 15 of 37 (41%) mantle cell lymphomas by a fluorescence in situ hybridization (FISH) analysis. However, the frequency and significance of 13q loss in the variety of types of lymphoma have not been elucidated.
To clarify the role of the putative TSGs on the long arm of chromosome 13 in lymphomagenesis, we analyzed a relatively large number of lymphomas (43) for chromosome aberrations at the 13q14 region, and we found that the region was lost in a variety of types of lymphoma, including both B-and T-NHL and Hodgkin's disease (HD), and that the 13q14 deletion was more prominent in aggressive NHL than in indolent NHL.
Materials and methods

Samples
A total of 43 lymphoma samples was obtained at the biopsy of pathologic lymph nodes or pleural effusions from 43 patients after informed consent was obtained according to the recommendations of the Declaration of Helsinki (diagnosis between January 1992 and May 1996). The fresh lymph nodes were divided for morphologic, immunologic and cytogenetic studies. Their cells were cryopreserved for various periods of time before DNA extraction. All histologic material was reviewed by the same pathologist and classified according to the Working Formulation for Clinical Usage and the revised European-American classification of lymphoid neoplasms. These samples included 23 aggressive B cell diffuse lymphomas (16 diffuse large cell, four diffuse mixed and three diffuse small cleaved), six low-grade B cell lymphomas (four follicular mixed, one follicular small cleaved and one small lymphocytic), seven T cell lymphomas (three angioimmunoblastic, one diffuse large cell, one lymphoblastic, one anaplastic large cell, and one Lennert type), and seven HD (two mixed cellularity, one nodular sclerosis and four lymphocyte predominance). The B cell/T cell lineages of all cases were confirmed by flow cytometry, immunohistochemistry or Ig genes/T cell receptor gene rearrangements. These analyses also served to ensure that there was a sufficient percentage (at least 30% and usually more than 50%) of tumor cells present for the loss of heterozygosity (LOH) analyses. The corresponding normal DNAs were obtained from the peripheral blood. Genomic DNA extraction was performed as described elsewhere. 22 
FISH analyses
Cells for FISH studies were obtained from a total of 43 lymphoma samples. Single-color FISH was performed by using 13q14-specific probes, LSI-13/RB1 or LSI-D13S319 spectrum orange (Vysis, Downers Grove, IL, USA). Two-color FISH was also performed for an analysis of 12 cases by using 13q14-specific probe-LSI-RB1/LSI-21 directly labeled with spectrum green/orange (Vysis). Tissue samples were incubated in 75 mm potassium chloride solution for 30 min, and fixed by the addition of an equal volume of methanol/acetic acid (3:1). The cell suspensions were dropped on to slides, air-dried and incubated for 2 h at 65°C. The cell preparations were then denatured in a 70% formamide/2 × standard saline citrate solution at 75°C for 2 min, dehydrated in 70, 85 and 100% ethanol, and air-dried. The hybridization mixture contained 10 l of each of the labeled probes. The slides were counterstained with 0.2 m 4,6-diamidino-2-phenylindole in an antifade solution.
A fluorescence microscope (BX60 F-3, Olympus, Tokyo, Japan) was used for the simultaneous visualization of spectrum orange or spectrum green/orange signals. At least 100 nonoverlapping nuclei with intact morphology based on 4,6-diamidino-2-phenylindole counterstaining were scored to determine the number of hybridization signals for each probe. The hybridization of the LSI-RB1 or LSI-D13S319 probe and of the LSI-21 probe with normal lymphocytes yielded two signals in more than 90% of the interphase cells, and the percentages of cells exhibiting one signal were 3.4% (standard deviation (s.d.) = 1.3), 3.6% (s.d. = 2.1) and 5.2% (s.d. = 1.9) for LSI-RB1, LSI-D13S319 and LSI-21, respectively, whereas the percentages of cells with three or more signals were 1.7% (s.d. = 0.6), 1.8% (s.d. = 0.8) and 3.6% (s.d. = 1.5) for LSI-RB1, LSI-D13S319 and LSI-21, respectively. Therefore, based on the mean +3s.d., we defined the criteria as follows: monosomy was identified in the presence of Ͼ10.9% of the interphase cells with one signal, and polysomy in the presence of Ͼ8.1% of the cells with three or more signals.
LOH analysis using microsatellite markers
The LOH analysis was performed by the polymerase chain reaction (PCR) amplification of microsatellite sequences at D13S168, RB1 and D13S272. The oligonucleotides used as primers were based on sequences derived from the Genethon microsatellite map and Gene Data Bank (Baltimore, MD, USA), [23] [24] [25] and were synthesized by Bex (Tokyo, Japan). The PCR reactions were performed in a final reaction volume of 20 l containing 100 ng of DNA template, 1-2 mm MgCl 2 , 10 pmol of each primer, 250 m of dNTPs, 1 unit of Taq DNA polymerase (GIBCO BRL, Gaithersburg, MD, USA), and 3 Ci of ␣-32 P dCTP (3000 Ci/mmol) in the specified buffer. Thirtyfive cycles of denaturing for 40 s at 94°C, annealing for 30 s at 55°C and extending for 1 min at 72°C were done in a Perkin-Elmer (Norwalk, CT, USA) 9600 Gene Amp PCR system. After amplification, the PCR samples were diluted five-fold in loading buffer containing 20 mm EDTA, 96% formamide and 0.05% of both bromophenol blue and xylene cyanol. The products were heated to 95°C for 5 min, and 1.5 l of each sample was electrophoresed through a 6% polyacrylamide gel containing 8.3 mol/l urea for 3-4 h at 83 W. Subsequently, the gels were dried and subjected to autoradiography using Fuji RX film (Fuji Photo Film, Kanagawa, Japan) at −80°C. For each experiment, negative DNAs and water controls were run in parallel. LOH was inferred when a visible reduction was measured in the ratio of the allele radiographic signal intensities in the tumour sample relative to that in the corresponding normal sample.
Cytogenetic analysis
Chromosome studies were carried out on lymph node cells and/or lymphocytes in pleural effusions after an 18 h in vitro culture. Cells were exposed to 2.5 g/ml of ethidium bromide and to 0.03 g/ml of colcemid for the final 2 h and 0.5 h, respectively, and harvested according to standard cytogenetic techniques. About 30 metaphases per patient were analyzed to determine clonal chromosome abnormalities after the Qbanding method was applied. Karyotypes were described in accordance with the International System for Human Cytogenetic Nomenclature: Guidelines for Cancer Cytogenetics (ISCN, 1991) .
Results
FISH at the RB1 and D13S319 loci in 43 primary lymphomas
To clarify the frequency of chromosome 13q14 abnormalities in lymphoma, we analyzed by FISH a total of 43 primary lymphomas, including 36 NHLs of both B and T cell type and seven HDs. Monosomy at either or both the RB1 and D13S319 loci was detected in 13 of the 36 (36%) NHLs, and polysomy at either or both loci was detected in eight of the 36 (22%) NHLs (Table 1 and Figure 1) . Thus, the total frequency of 13q14 abnormalities in NHL amounted to 58% (21 of 36 NHLs). Monosomy of both loci at 13q14 was detected only in six aggressive NHLs. Deletion of D13S319 only (in the presence of two RB1 signals) was detected in only one aggressive NHL (No. 11) while deletion of RB1 only (in the presence of two D13S319 signals) was detected in eight cases (one indolent NHL, five aggressive NHLs and two HDs) mak- ing RB1 deletion the most frequent cytologic change among our patients (Table 1) . A summary of the results is provided in Table 1 . The frequency of 13q14 deletion was quite high in aggressive NHL (12 of 30 cases; 40%) including eight of 16 (50%) B cell DLCL, one of three (33%) diffuse small cleaved lymphomas and three of seven (43%) T cell lymphomas (two angioimmunoblastic and one anaplastic large cell), although the number of cases analyzed is too small to warrant a conclusion regarding the frequency of 13q14 deletion in each subtype. The 13q14 deletion was also found in one of six (17%) low-grade B cell lymphomas (one follicular mixed) and in two of seven (29%) HDs (two mixed cellularity).
LOH and FISH analyses in 15 lymphomas and comparison of the results
To investigate 13q14 deletion, we analyzed 15 of 43 lymphomas for LOH using three microsatellite markers (D13S168, 
RB1 and D13S272).
Five of these cases (Nos 11-14 and 20) had been previously found positive for 13q14 deletion on FISH analysis. Four out of five of these deleted lymphomas (Nos [11] [12] [13] [14] had LOH for at least one of the three loci analyzed (Table 1 and Figure 2 ), confirming the finding of 13q14 deletion at either or both RB1 and D13S319 loci by FISH analysis. In two of the four cases (Nos 13 and 14) allelic deletion was detected at all the informative loci by LOH analysis, including both the RB1 and D13S319 loci also showing deletion by FISH, suggesting loss of the whole chromosome 13q in these cases. In case No. 11 the allelic deletion at the D13S319 locus was detected by both LOH and FISH analysis while deletion at the RB1 locus was scored by LOH analysis but not by FISH. In case No. 12, while loss at the RB1 locus was scored by both techniques, deletion at D13S319 was detected by FISH but not by LOH analysis using D13S272 marker located in close vicinity of D13S319. Finally, one case (No. 20) had an RB1 deletion as shown only by FISH but not by LOH analysis.
Two cases with deletion at the D13S168 locus shown by LOH revealed tetrasomy (No. 4, Figure 1 ) or trisomy (No. 8) at both the RB1 and D13S319 loci by FISH. From these results, we concluded that the two cases did not have deletion but rather had polysomy.
Conventional cytogenetics
Of the 30 patients from whom evaluable metaphases were obtained, 13 cases (43%) had clonal chromosomal abnormalities (Table 1 ). Although monosomy 13 was detected in three cases (Nos 23, 34 and 36; 9%), no structural abnormality including the chromosome 13q region was detected at the cytogenetic level, except for one case (No. 7) which had add(13)(q34). No structural abnormalities of chromosome 21 were detected, but monosomy 21 was found in the minor clones originating from two patients (Nos 27 and 34). t(14;18)(q32;q21) was seen in one of four follicular lymphomas, in one DLCL and in one small lymphocytic lymphoma. Five cases including two DLCLs, two follicular lymphomas and one HD had add (14) ; three cases including two diffuse and one T cell lymphomas had del(2); del(18) was found in two diffuse and one follicular lymphomas. Finally, two cases including one diffuse and one small lymphocytic lymphomas had del (3) .
A karyotype analysis was available in 11 of the 15 cases with either NHL or HD with chromosome 13q14 deletion and in four of the eight cases with chromosome 13q14 polysomy detected by FISH analysis. In three cases with monosomy 13 (Nos 23, 34 and 36) an RB1 deletion was also shown by FISH. In the other eight cases neither monosomy nor any structural abnormality including the chromosome arm 13q region was detected. These results indicated that most of the 13q14 alterations shown here were so subtle that they were detected only by molecular analyses.
Discussion
The development of a tumor is believed to occur through a multistep process in which the genetic alterations promoting tumorigenesis are accumulated, and the inactivation of recessive TSGs plays an important role in this process. 5 Previously published data showed that the allelic loss of the long arm of chromosome 13 occurred in a subset of cases with NHL: 13q14 deletions were found in three of 12 follicular lymphomas, 20 and the hemizygous deletion of the RB1 locus was seen in 15 of 37 (41%) mantle cell lymphomas, 21 suggesting the existence of the putative TSG(s) on the 13q14 region in lymphomagenesis. To clarify the frequency of 13q loss in the variety of types of lymphoma, we screened 43 lymphoma cases, including both indolent and aggressive NHL and HD, for loss of genetic material on the chromosome arm 13q. We performed a FISH analysis of 43 cases and an LOH analysis of 15 of the 43 cases. We determined the frequency by the screening of 43 lymphoma cases by FISH as 36% (13 of the 36) in NHLs: this frequency is comparable to that of previous reports. 20, 21 In addition, we also found that the frequency of 13q14 deletion was quite high in aggressive NHL (40%) including both B-and T-NHL compared with indolent NHL (17%). The 13q14 deletion was not specific to NHL but was also shown in some HD (29%). Our results indicate that the 13q14 deletion is of pathogenic significance in the formation or development of various types of lymphoma, and that it may be related to the aggressiveness of this malignancy.
We could examine only 15 of the 43 lymphoma cases by LOH analysis because of an inability to obtain normal control lymphocytes from the remaining cases. We confirmed the 13q deletion for at least one informative loci analyzed in four of five positive cases in which an allele loss was detected by FISH analysis. A discrepancy between the results obtained by FISH and LOH analyses was shown in three cases analyzed here. In the first case (No. 20: positive by FISH but negative by LOH at RB1 locus), the LOH results might have been hampered by the presence of contaminating normal alleles in the tumor sample, as suggested by the low percentage of cells (24%) with one RB1 signal detected by FISH. In the second case (No. 11, positive on LOH but negative on FISH at RB1 locus), one explanation is that mitotic recombination between sister chromosomes may cause LOH, but be detectable as a disomy by FISH analysis. Another possibility is that duplication of a remaining allele with the loss of another allele may show LOH but disomy on FISH analysis. The third possibility is that the markers used for FISH and LOH analysis do not cover exactly the same genomic interval, so it is possible that a deletion breakpoint could lie between the two regions explored by the two probes, thus explaining the discrepancy between the two results. Last, the criteria for monosomy by FISH analysis, which is based on the mean +3s.d. (existence of more than 10.9% cells with one signal), may be so strict as to cause false negative findings. In the third case (No. 12) with an allelic deletion at RB1 locus detected by both the LOH and FISH analyses, an allele loss was also seen at D13S319 locus by FISH and at D13S168 locus by LOH analysis but not at D13S272 locus by LOH analysis. It is speculated that this case may have a microdeletion between the D13S168 and D13S319 loci centromeric to the D13S272 locus and telomeric to the D13S287 locus, because the relative order of 13q markers is Cen-D13S287-D13S168-RB1-D13S319-D13S272-D13S270-Tel by physical mapping data. Additional LOH analyses in this case revealed that heterozygosity was retained at both the D13S287 locus centromeric to D13S168 and the D13S270 locus telomeric to D13S272. This may support the above speculation (data not shown). In the remaining cases, the results of the two methods were well matched. These results indicated that the two methods can compensate for each other to improve interpretation of the results.
Several groups investigated the RB1 protein expression in B cell NHLs and reported that RB1 protein was not present or markedly reduced in a subset of primary NHLs and some cell lines.
26- 28 Martinez et al 27 analyzed the RB1 expression by immunohistochemistry in 97 primary lymphomas, including low-grade and high-grade NHLs and HDs, and found that 10 of 62 (16%) high-grade NHLs had no RB1 protein expression. They suggested a possible role for RB1 gene alterations in lymphoid malignancies. Unfortunately, we could not analyze the RB1 gene expression in the lymphomas used in this study because of a shortage of tissue samples. However, it is unlikely that the RB1 gene is the target of LOH at 13q14, since the frequency of 13q14 deletion in the aggressive lymphomas (40%) clearly exceeded that of the RB1 gene inactivation (16%) shown by Martinez et al. 27 The possibility remains that the decreased gene dosage by LOH may reduce the RB1 gene expression and be relevant for the disease. Deletions and rearrangements involving chromosome arm 13q have been reported in a number of human tumors such as retinoblastoma and lung cancer as well as hematopoietic malignancies. 5 In CLL, homozygous deletions and/or translocations involving chromosome band 13q14 represent one of the most frequent (24-60%) abnormalities. 29 Taken together, these and the present findings suggest that the same TSG(s) on 13q14 may play a common role in the formation or development of these two distinct mature lymphoid malignancies. Liu et al 30 recently identified two strong candidate genes as TSGs in the 13q14 region, Leu1 and Leu2, the first exons of which were deleted in all CLL cases with 13q14 deletion examined, but the significance of the gene alteration in CLL and other malignancies with 13q14 deletion has not been elucidated.
In summary, previously published data showed that the loss of genetic material on 13q14 may have a specific role in the development of most CLLs, and in some types of NHLs. Our present data show that the 13q14 deletion is not specific to a subset of B-NHL or CLL, but is rather a relatively common phenomenon in a variety of types of lymphoma, and that the 13q loss is prominent in aggressive NHL, suggesting that the alteration may be related to the aggressiveness of this malignancy. Further studies are required to confirm the frequency and the significance of 13q14 deletions, and to identify the TSG(s) on chromosome 13q14 which are inactivated in a variety of types of mature lymphoid malignancies.
